Triplex-Induced Apoptosis for Resistant HER2 Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting the HER2 pathway in breast cancer, such as Herceptin, face limitations due to acquired resistance, necessitating new therapeutic approaches that can selectively induce apoptosis in cancer cells while sparing normal cells.
Innovation Solution
The method involves introducing triplex-forming molecules, like triplex-forming oligonucleotides (TFOs), into cancer cells with amplified HER2 genes to form multiple triplex structures, overwhelming the cell's DNA repair capacity and inducing apoptosis, thereby avoiding adverse effects on healthy cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Herceptin is used to block HER2 pathway, then cancer cell growth is inhibited, but acquired resistance develops
Solution Approach 1:
Instead of blocking HER2 signaling to inhibit growth (Herceptin approach), the invention inverts the approach by directly inducing apoptosis through triplex formation at DNA level, bypassing the HER2 signaling pathway entirely and overcoming resistance mechanisms
Solution Approach 2:
The invention introduces triplex-forming oligonucleotides as an intermediary that binds to polypurine sites in amplified genes, forming triplex structures that trigger apoptosis independently of HER2 pathway status or resistance mechanisms
2Object-affected harmful factors
If triplex-forming molecules are introduced to induce apoptosis, then cancer cells are selectively killed, but DNA damage must be sufficient to overwhelm repair capacity
Solution Approach 1:
The invention applies local quality by targeting triplex formation specifically at polypurine sites within amplified cancer genes, creating localized DNA structural changes that trigger apoptosis only in cells with gene amplification, thereby achieving selectivity
Solution Approach 2:
The invention employs partial action by forming multiple triplexes at multiple polypurine sites within amplified genes, creating sufficient cumulative DNA damage to overwhelm repair capacity and trigger apoptosis, while the number of triplexes needed is less than total possible sites
3Reliability
If multiple triplexes are formed to induce apoptosis, then DNA repair capacity is overwhelmed, but normal cells with two gene copies are spared
Solution Approach 1:
The invention exploits the local quality difference between cancer cells (with gene amplification containing multiple polypurine sites) and normal cells (with two gene copies), enabling selective triplex formation and apoptosis induction only in cancer cells
Solution Approach 2:
The invention utilizes parameter changes in gene copy number between normal and cancer cells, where amplified genes provide multiple target sites for triplex formation, creating a quantitative difference that enables selective apoptosis induction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively induces apoptosis in HER2-positive breast cancer cells, including those resistant to Herceptin, by exploiting the unique genetic features of malignant cells, thereby overcoming the limitations of existing therapies and providing a novel mechanism for treating primary and metastatic breast cancer.
Implementation Method 1
Described herein is a method of triplex-induced apoptosis, in which multiple triplexes are formed in cells, referred to as target cells, in which gene amplification has occurred
Data Source
AI summary
Described herein are methods of triplex-induced apoptosis, in which multiple triplexes are formed in cells in which gene amplification has occurred (cells comprising/characterized by at least one amplified gene), referred to as target cells, and apoptosis is induced in the target cells.